ArticleBioorganic & medicinal chemistry letters2011
Structure-activity studies of RNA-binding oxazolidinone derivatives.
Article in Bioorganic & medicinal chemistry letters, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 34 citations in OpenAlex.
- Harnessing Computational Approaches for RNA-Targeted Drug Discovery.RNA nanomed · 2024Article
- Oxazolidinones as versatile scaffolds in medicinal chemistry.RSC medicinal chemistry · 2023Review
- 4-Aminoquinolines modulate RNA structure and function: Pharmacophore implications of a conformationally restricted polyamine.Biochemical and biophysical research communications · 2023Article
- Multiassay Profiling of a Focused Small Molecule Library Reveals Predictive Bidirectional Modulation of the lncRNA MALAT1 Triplex StabilityACS chemical biology · 2022Article
- Quantitative Structure-Activity Relationship (QSAR) Study Predicts Small-Molecule Binding to RNA Structure.Journal of medicinal chemistry · 2022Article
- A New Promising Anti-Infective Agent Inhibits Biofilm Growth by Targeting Simultaneously a Conserved RNA Function That Controls Multiple Genes.Antibiotics (Basel, Switzerland) · 2021Article
- Small-Molecule Antibiotics Inhibiting tRNA-Regulated Gene Expression Is a Viable Strategy for Targeting Gram-Positive Bacteria.Antimicrobial agents and chemotherapy · 2020Article
- Small molecule-RNA targeting: starting with the fundamentals.Chemical communications (Cambridge, England) · 2020Article
- Driving factors in amiloride recognition of HIV RNA targets.Organic & biomolecular chemistry · 2019Article
- Direct modulation of T-box riboswitch-controlled transcription by protein synthesis inhibitors.Nucleic acids research · 2017Article
- Amiloride as a new RNA-binding scaffold with activity against HIV-1 TAR.MedChemComm · 2017Article
- Identification of Spermidine Binding Site in T-box Riboswitch Antiterminator RNA.Chemical biology & drug design · 2016Article
- Factors that influence T box riboswitch efficacy and tRNA affinity.Bioorganic & medicinal chemistry · 2015Article
- Methods to enable the design of bioactive small molecules targeting RNA.Organic & biomolecular chemistry · 2014Review
- The impact of a ligand binding on strand migration in the SAM-I riboswitch.PLoS computational biology · 2013Article
- Basis for ligand discrimination between ON and OFF state riboswitch conformations: the case of the SAM-I riboswitch.RNA (New York, N.Y.) · 2012Article
- Interfacing medicinal chemistry with structural bioinformatics: implications for T box riboswitch RNA drug discovery.BMC bioinformatics · 2012Article
- Ligand-induced changes in T box antiterminator RNA stability.Chemical biology & drug design · 2012Article
- Anisotropy studies of tRNA-T box antiterminator RNA complex in the presence of 1,4-disubstituted 1,2,3-triazoles.Bioorganic & medicinal chemistry letters · 2011Article
- Synthesis and stereospecificity of 4,5-disubstituted oxazolidinone ligands binding to T-box riboswitch RNA.Journal of medicinal chemistry · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
The structure-activity relationship of a series of oxazolidinones binding to T-box riboswitch antiterminator RNA has been investigated. Oxazolidinones differentially substituted at C-5 were prepared and the ligand-induced fluorescence resonance energy transfer (FRET) changes in FRET-labeled antiterminator model RNA were assayed. Both qualitative and quantitative analysis of the structure-activity relationship indicate that hydrogen bonding and hydrophobic properties play a significant role in ligand binding.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.